)
Milestone Pharmaceuticals (MIST) investor relations material
Milestone Pharmaceuticals Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
The annual meeting is scheduled for June 10, 2026, to be held virtually, allowing shareholders to vote and participate online.
Shareholders will vote on director elections, auditor appointment, an equity plan amendment, and a say-on-pay proposal.
Proxy materials, including the annual report, are available online, with options for electronic or paper delivery.
Voting can be done online, by phone, mail, or during the virtual meeting, with detailed instructions provided.
Voting matters and shareholder proposals
Election of eight directors to serve until the 2027 annual meeting.
Ratification of PricewaterhouseCoopers LLP as auditor until the 2027 annual meeting and authorization for the board to set remuneration.
Approval of an amendment to the 2019 Equity Incentive Plan to increase shares authorized for issuance by 6,800,000.
Non-binding advisory vote on executive compensation (say-on-pay).
Shareholder proposals and director nominations for the 2027 meeting must be submitted by specified deadlines.
Board of directors and corporate governance
Board consists of eight members, seven of whom are independent; the CEO is the only non-independent director.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.
The board chair is independent, and directors are elected annually with no classified board structure.
Directors had a 99% attendance rate for board meetings and 93% for committee meetings in the last year.
The company maintains a robust code of business conduct and ethics and prohibits pledging or margin purchases of its securities by insiders.
- Virtual meeting to vote on directors, auditors, equity plan increase, and executive pay.MIST
Proxy filing30 Apr 2026 - CARDAMYST launches as the first new PSVT therapy in decades, targeting rapid market adoption.MIST
Corporate presentation29 Apr 2026 - Etripamil offers rapid, self-administered relief for PSVT, filling a key unmet clinical need.MIST
Study update23 Apr 2026 - Cardamyst targets FDA approval and mid-2025 launch, addressing major unmet needs in PSVT.MIST
Investor update23 Apr 2026 - FDA decision on CARDAMYST pending; net loss narrows as launch and new trials approach.MIST
Q4 202423 Apr 2026 - CARDAMYST launches with strong clinical data, broad provider targeting, and robust financial runway.MIST
25th Annual Needham Virtual Healthcare Conference13 Apr 2026 - CARDAMYST launched with strong early demand and $200M in cash, supporting growth into 2027.MIST
Q4 202520 Mar 2026 - CARDAMYST launches for PSVT with rapid uptake, robust support, and plans for AFib expansion.MIST
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - FDA-approved CARDAMYST targets rapid PSVT relief, unlocking a $1B+ market opportunity.MIST
Corporate presentation3 Mar 2026
Next Milestone Pharmaceuticals earnings date
Next Milestone Pharmaceuticals earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage